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Abstract : 
The prognosis of chromophobe renal cell carcinoma (RCC) is generally favorable. However, some 
investigations argue against this point of view. In this article, we performed clinicopathologic study of 
eight cases of chromophobe RCC with focus on prognostic factors. The incidence of chromophobe RCC 
accounts for 7.3% of total renal tumors. In six patients, tumor was incidentally discovered. Aggressive 
form was observed in three patients who died of disease in one or showed the distant metastasis in two. 
Four tumors macroscopically showed more than 8 cm in maximum diameter, which all showed necrosis. 
Among these tumors, three tumors showed pathologically more than stage III, more than CTG 2, and 
vascular invasion. Two among these three tumors contained unusual morphological finding, namely 
neuroendocrine differentiation or breast cancer-like morphology. Five tumors showed CTG 1 and Stage 
I, which showed neither recurrence nor metastasis. Finally, several factors such as more than 8cm in 
maximum diameter, macroscopic necrosis, vascular invasion, more than CTG 2 and usual histologic 
features including neuroendocrine differentiation and mammary-like carcinoma may be worse prognostic 
indicators in chromophobe RCC.
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INTRODUCTION
The prognosis on chromophobe renal cell 
carcinoma (RCC) is debatable to date.1-12 The 
Fuhrman grading system has been widely used 
in clear cell and papillary RCC and has been 
recently revised as ISUP grading system with 
special emphasis on nucleolar characteristics. 
13,14 However, Fuhrman grade and revised ISUP 
grade are not applicable in chromophobe RCC.14-
17 Recently, Paner et al. proposed the new grading 
system, Chromophobe Tumor Grade (CTG) 
instead of Fuhrman nuclear grade.18 However, 
the clinical and biological significance of CTG 
was controversial to date.18-20 In this study, we 
performed the clinicopathologic study of eight cases 
with chromophobe RCC with special emphasis on 
prognostic factors. 
MATERIALS AND METHODS
Among surgically resected one-hundred nine 
renal tumors between January 2007 and December 
2016, eight cases with chromophobe RCC has been 
selected in the present study. Two cases have been 
previously reported.1-22 Clinical finding (sex, age, 
symptoms, imaging findings and clinical stage) 
macroscopic findings (color, necrosis, hemorrhage 
and cyst), microscopic findings (major subtype, 
other histologic features, Fuhrman Grade, CTG, 
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vascular invasion, lymph node metastasis and 
pathological stage) and therapy/outcome were 
retrospectively examined for each case. CTG 
was evaluated according to the Paner’s criteria.18 
Additionally, the progression-free survival of 7 
cases with chromophobe RCC was compared with 
that of 24 cases with clear cell RCC diagnosed 
between 2010 and 2011, using Kaplan-Meier method 
and the long-rank test. All P values were two sided 
and a P<0.05 was considered to be significant. 
RESULTS
Clinical features
The clinical information is summarized in Table 1. 
Eight cases with chromophobe RCC accounted for 
7.3% of one-hundred nine renal tumors surgically 
resected during this period. Patients consisted of 
five men and three women. The age of patients 
ranged from 42 to 80 years with a mean age of 
63.8 years. In six patients, tumor was incidentally 
discovered. One patient presented with hematuria 
and another patient presented with weight loss. 
The dynamic computed tomography scan showed 
heterogeneous enhancement in four patients, 
homogenous enhancement in one patient and 
no enhancement in two patients. The imaging 
information of the remaining one patient was not 
available. The clinical stage was composed of five 
tumors in stage I, two in stage III and one in stage 
IV. 
Pathological findings
Macroscopic findings
Macroscopic features are summarized in Table 
2. The tumor size ranged from 1.9 to 22 cm with 
a mean size of 7.5 cm. The cut surface showed in 
beige or light brown to beige in all tumors, and 
one tumor additionally showed focal yellow area. 
Necrosis and hemorrhage were observed in four 
and five tumors, respectively (Fig.1). Cyst formation 
was identified in only one tumor. 
Microscopic findings
Histologic features are summarized in Table 
3. The major subtype consisted of five cases in 
typical variant (Fig. 2a) and three 
cases in eosinophil ic  variant 
(Fig. 2b). Additionally, nested or 
trabecular growth pattern (Fig. 2c) 
on the fibrotic stroma resembling 
mammary invasive carcinoma, 
NOS was seen in  one tumor. 
Neuroendocrine differentiation 
(30%) (Fig. 2d) and sarcomatoid 
change (1%) (Fig. 2e) were observed 
in one tumor. Tumor cells showing 
pleomorphism, giant cells and 
bizarre nuclei (Fig. 2f ) were noted 
in one tumor. Fuhrman grade 
consisted of five tumors in grade 2, 
one in grade 3 and two in grade 4. 
CTG was composed of five tumors 
in grade 1 (Fig. 2a, b), one in grade 
2 (Fig. 2g) and two in grade 3 (Fig. 
2e, f ). Vascular invasion (Fig. 2h) 
was recognized in three tumors. 
TABLE 1: Clinical summary 
Case Sex Age Symptom Enhance CT findings cStage 
1 M 53 incidentally found ? Stage I 
2 F 42 hematuria heterogeneous enhance Stage IV 
3 M 80 incidentally found heterogeneous enhance Stage I 
4 M 79 weight loss heterogeneous enhance Stage III 
5 M 54 incidentally found homogenous enhance Stage I 
6 F 74 incidentally found no enhance Stage I 
7 F 68 incidentally found no enhance Stage I 
8 M 66 incidentally found heterogeneous enhance Stage III 
M, male: F, female. 
TABLE 1: Clinical summary
TABLE 2: Summary of macroscopic findings 
Case Size Cut surface color Necrosis Hemorrhage Cyst 
1 4cm Beige - + - 
2 8cm Beige~light brown + + - 
3 1.9cm Beige~light brown - + - 
4 22cm Beige + + - 
5 3.1cm light brown - - - 
6 8.5cm light brown~beige + - - 
7 4.5cm Beige - - + 
8 8.2cm light brown~beige~yellow + + - 
+, present; -, absent. 
 
TABLE 2: Summary of macro copic findings
9Therapy, follow-up duration and outcome
All data are summarized in Table 4. 
Surgical treatment was performed in all 
cases, which consisted of four tumors 
in radical nephrectomy and four in 
partial resection. Additionally, VEGF/
PDGF inhibitor was administered for 
metastatic disease in two patients (cases 
2 and 8). Furthermore, one patient 
(case 2) received mTOR inhibitor and 
underwent γ-knife for brain metastasis. 
The follow-up data was available in 
seven patients. The follow-up duration 
ranged from 21 to 108 months with a 
mean of 45.7 months. Four patients (cases 1, 5, 6, 
and 7) was alive without disease and two patients 
(cases 4 and 8) were alive with metastasis to lung/
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Metastasis to lymph nodes was noted in one tumor. 
The pathological stage consisted of five tumors in 
stage I, two in stage III and one in stage IV. 
TABLE3: Summary of microscopic findings 
Case Variant Other morphology FG CTG VI LNM pStage 
1 E none G2 G1 -  Stage I 
2 T nesting, trabecular  G3 G2 + + Stage IV 
3 E none G2 G1 -  Stage I 
4 T NE (30%),  sarcomatoid (1%) G4 G3 + 
 Stage III 
5 T none G2 G1 -  Stage I 
6 E none G2 G1 -  Stage I 
7 T none G2 G1 -  Stage I 
8 T none G4 G3 + - Stage III 
T, typical; E, eosinophilic; NE, neuroendocrine; FG, Fuhrman Grade; 
CTG, chromophobe tumor grade; VI, vascular invasion, LNM, lymph node 
metastasis; +, present; -, absent. 
 Fig.1 
 Fig.2a 
 Fig.2b 
 Fig.2c 
 Fig.2d 
 Fig.2e 
 Fig.2f 
 Fig.2g 
 Fig.2h 
TABLE3: Summary of microscopic findings
FIG.1: Macroscopic finding of chromophobe RCC. Hemorrhage and necrosis are seen. 
FIG.2: Microscopic finding of chromophobe RCC. (a) Typical variant. Pale cells predominately proliferate. Chromophobe 
Tumor Grade (CTG) 1. (b) Eosinophilic variant. Eosinophilic cells predominately proliferate. CTG 1. (c) Nesting or 
trabecular growth pattern is seen on the fibrotic stroma. (d) Rosette formation is observed. (e) Spindle neoplastic cells 
proliferate. This finding corresponds to Fuhrman Grade 4 and CTG 3. (f) Tumor cells demonstrate pleomorphism, giant 
cells and bizarre nuclei. This finding corresponds to Fuhrman Grade 4 and CTG 3. (g) CTG 2. Nuclear crowding is 
present. (h) Vascular invasion is present. 
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lymph nodes and liver, at 52 and 23 months after 
the operation, respectively. In patient case 8, live 
metastasis appeared during the follow-up period. 
One patient (case 2) died of disease at 21 months 
postoperatively. 
Comparison of Progression-free survival between 
chromophobe RCC and clear cell RCC 
Unexpectedly, progression-free survival of 
chromophobe RCC was worse than that of clear cell 
RCC. However, there was statistically no significant 
difference between two groups (Fig. 3). 
DISCUSSION
In the present study, the incidence 
of chromophobe RCC was 7.3% of 
all  renal tumors. This frequency 
is compatible with the previous 
reports.1,11 Patients with chromophobe 
RCC were significantly younger 
and tended to be more frequently 
female.6,9,12 However, male patients 
were predominant in this study. 
Imaging analysis ,  chromophobe 
RCC often showed homogenous 
enhancement in computed tomography 
scan.23 At contrast, chromophobe RCC 
showed heterogeneous enhancement 
in four tumors. This result may reflect macroscopic 
hemorrhage or necrosis. 
The  prognos i s  o f  chromophobe  RCC i s 
controversial. Some reports show better prognosis 
in chromophobe RCC than that in clear cell 
RCC1,8,10,11, whereas other reports demonstrate 
that the prognosis of these two RCC is identical.5,6 
The results in the present study support the 
latter hypothesis. As other prognostic indicators 
of chromophobe RCC, more than 8cm in tumor 
size, the association of papillary RCC, necrosis, 
vascular invasion, sarcomatoid change, CTG and 
pStage have been previously suggested.3,7,10,11,20,24 
In the present study, there was no case with 
the association of papillary RCC. However, it is 
possible that all factors except for the association 
of papillary RCC may be involved in the aggressive 
biological behavior in chromophobe RCC on 
the basis of results of this study. However, the 
number of cases with chromophobe RCC in the 
present study is too small to draw the definitive 
conclusion. Regarding the nuclear grade, it has 
been described that Fuhrman Grade is associated 
with the prognosis of chromophobe RCC in some 
reports.3,25 However, it is widely accepted that 
there is no association between Fuhrman Grade 
and prognosis of chromophobe RCC and this idea 
has been incorporated into the recent ISUP grading 
system.14-17 Recently, Paner et al. have proposed the 
TABLE 4: Summary of therapy, follow-up duration and outcome 
Case Surgery Additional therapy 
Follow-up 
duration Clinical outcome 
1 P none 108 months AWOD 
2 R 
VEFG・PDGF-I,  
mTOR-I,  
γ-knife  
21 months DOD 
3 P none - Lost 
4 R none 52 months AWD, Lung, LN metastasis 
5 P none 52 months AWOD 
6 R none 39 months AWOD 
7 P none 25 months AWOD 
8 R VEFG・PDGF-I 23 months AWD, Liver metastasis 
P, partial resection; R, radical nephrectomy; AWOD, alive without disease; 
AWD, alive with disease: DOD, die of disease, LN, lymph node.
TABLE 4: Summary of therapy, follow-up duration and outcome
 Fig.3 
FIG. 3: Progression-free survival curve on two 
histologic subtypes. There was no significant difference 
between chromophobe and clear cell RCC groups.
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new grading system for chromophobe RCC, namely 
CTG.18 They concluded that CTG is associated with 
the prognosis of chromophobe RCC,18 whereas 
Przybycin et al. and Cheville et al. argue against 
this opinion.19,20 In this study, we found that the 
presence of usual histological features such as 
neuroendocrine morphology or breast cancer-like 
morphology may be worse prognostic indicators of 
chromophobe RCC.21,22 Neuroendocrine morphology 
may be related to increased density of neoplastic 
cells with CTG 2 and be associated with loss of 
chromosomes 4, 5 and 16p.26 Oncofetal protein, 
IMP3, may be a useful predictor of metastasis in 
chromophobe RCC.27
R e g a r d i n g  t h e  t h e r a p y  o f  m e t a s t a t i c 
chromophobe RCC,  VEGF/PDGF inhibitor 
or mTOR inhibitors has been tried and some 
cases respond to these therapies.28-31 However, 
these agents seem to be usually less reactive in 
chromophobe RCC than clear cell RCC. Further 
examination in a large scale study will be required 
in the near future. It seems to be unlikely that 
immune checkpoint therapy will be available in 
chromophobe RCC.32 
In conclusion, several factors such as more than 
8cm in maximum diameter, macroscopic necrosis, 
vascular invasion, more than CTG 2 and usual 
histological features including neuroendocrine 
differentiation and mammary-like carcinoma may 
be worse prognostic indicators. 
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